Ketalar

Ketamine, the active ingredient in Ketalar, is an NMDA receptor antagonist presented as a sterile injectable solution for intramuscular and intravenous use. It provides dissociative anesthesia and analgesia, and is employed in the induction of general anesthesia, procedural sedation, and management of refractory pain in adult patients.

GNH USA supplies Ketalar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to strict quality standards and provides regulatory documentation for global distribution.

Ketamine acts as a dissociative anesthetic affecting the NMDA receptor pathway, and is indicated for several clinical situations.

- Induction of general anesthesia: provides rapid onset dissociative anesthesia facilitating endotracheal intubation and surgical anesthesia. - Procedural sedation: produces profound sedation and analgesia for short‑duration diagnostic or therapeutic procedures where airway protection is maintained. - Analgesia for refractory pain: offers analgesic effect in patients with severe, treatment‑resistant pain, often as an adjunct to other analgesics.

Ketamine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Emergence delirium or vivid dreams - Hypertension or tachycardia - Nausea and vomiting - Dizziness or visual disturbances - Salivation increase

Serious or Rare Side Effects: - Respiratory depression or airway obstruction - Severe hypertension or arrhythmia - Psychomimetic reactions (hallucinations, agitation) - Urinary tract toxicity with prolonged use - Hepatic enzyme elevation

Ketamine requires careful monitoring and specific safety measures before and during administration.

- Cardiovascular monitoring: observe blood pressure and heart rate due to possible hypertension and tachycardia. - Airway assessment: ensure readiness for airway support because of risk of laryngospasm or respiratory depression. - Psychiatric history: use caution in patients with schizophrenia or severe anxiety disorders. - Concomitant CNS depressants: avoid or adjust doses when combined with opioids, benzodiazepines, or alcohol. - Pregnancy and lactation: consider risk‑benefit ratio; use only if clearly needed. - Store at ambient temperature: keep in original container, protect from moisture and light.

Ketamine can interact with other medicines, altering its effects or safety profile.

Major Interactions (Avoid):\n- Concurrent use with other NMDA antagonists (e.g., dextromethorphan) may increase neurotoxicity. - MAO inhibitors: risk of hypertensive crisis. - Potent CYP2B6 or CYP3A4 inducers (e.g., rifampin) may reduce therapeutic levels.

Moderate Interactions (Monitor Closely): - CNS depressants (opioids, benzodiazepines): may enhance sedation and respiratory depression. - Sympathomimetic agents (e.g., epinephrine): may exacerbate hypertension. - Anticholinergic drugs: may increase salivation or airway secretions.